Free Trial
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

Arcutis Biotherapeutics logo
$15.31 -0.34 (-2.19%)
As of 10:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Key Stats

Today's Range
$15.14
$15.70
50-Day Range
$13.39
$16.89
52-Week Range
$8.03
$17.75
Volume
132,623 shs
Average Volume
2.09 million shs
Market Capitalization
$1.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.80
Consensus Rating
Moderate Buy

Company Overview

Arcutis Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

ARQT MarketRank™: 

Arcutis Biotherapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 526th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Arcutis Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.33) to ($0.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcutis Biotherapeutics is -20.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcutis Biotherapeutics is -20.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcutis Biotherapeutics has a P/B Ratio of 13.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arcutis Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.32% of the float of Arcutis Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Arcutis Biotherapeutics has recently decreased by 3.65%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arcutis Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Arcutis Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.32% of the float of Arcutis Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Arcutis Biotherapeutics has recently decreased by 3.65%, indicating that investor sentiment is improving.
  • News Sentiment

    Arcutis Biotherapeutics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 6 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcutis Biotherapeutics insiders have sold 1,675.41% more of their company's stock than they have bought. Specifically, they have bought $64,853.00 in company stock and sold $1,151,404.00 in company stock.

  • Percentage Held by Insiders

    Only 9.40% of the stock of Arcutis Biotherapeutics is held by insiders.

  • Read more about Arcutis Biotherapeutics' insider trading history.
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARQT Stock News Headlines

Biotech - Genetic Graphic
3 Biotech Catalysts Present Major Opportunity (ARQT)
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Arcutis to Present at Upcoming Investor Conferences
See More Headlines

ARQT Stock Analysis - Frequently Asked Questions

Arcutis Biotherapeutics' stock was trading at $13.93 on January 1st, 2025. Since then, ARQT stock has increased by 9.1% and is now trading at $15.2010.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. The company had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million. Arcutis Biotherapeutics had a negative net margin of 35.40% and a negative trailing twelve-month return on equity of 62.62%.
Read the conference call transcript
.

Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

Top institutional shareholders of Arcutis Biotherapeutics include Jennison Associates LLC (9.32%), Rubric Capital Management LP (8.97%), Frazier Life Sciences Management L.P. (8.24%) and State Street Corp (3.78%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Masaru Matsuda, Larry Todd Edwards, David Joseph Topper, Patrick Burnett, Howard G Welgus, Latha Vairavan, Patricia A Turney, Scott L Burrows, Patrick J Heron and Terrie Curran.
View institutional ownership trends
.

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA).

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARQT
CIK
1787306
Fax
N/A
Employees
150
Year Founded
2016

Price Target and Rating

High Price Target
$22.00
Low Price Target
$18.00
Potential Upside/Downside
+26.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$140.04 million
Net Margins
-35.40%
Pretax Margin
-35.04%
Return on Equity
-62.62%
Return on Assets
-25.16%

Debt

Debt-to-Equity Ratio
0.77
Current Ratio
3.20
Quick Ratio
3.04

Sales & Book Value

Annual Sales
$196.54 million
Price / Sales
9.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.16 per share
Price / Book
13.49

Miscellaneous

Outstanding Shares
119,900,000
Free Float
108,634,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
1.84

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ARQT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners